334 related articles for article (PubMed ID: 24659797)
1. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Olsson T; Boster A; Fernández Ó; Freedman MS; Pozzilli C; Bach D; Berkani O; Mueller MS; Sidorenko T; Radue EW; Melanson M
J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1198-208. PubMed ID: 24659797
[TBL] [Abstract][Full Text] [Related]
2. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
[TBL] [Abstract][Full Text] [Related]
3. An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Gisleskog PO; Valenzuela B; Scherz T; Burcklen M; Pérez-Ruixo JJ; Poggesi I
Clin Pharmacokinet; 2021 Sep; 60(9):1227-1237. PubMed ID: 33914286
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T
Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447
[TBL] [Abstract][Full Text] [Related]
6. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS; Pozzilli C; Havrdova EK; Lemle A; Burcklen M; Larbalestier A; Hennessy B; Sidorenko T; Vaclavkova A; Olsson T;
Neurology; 2022 Aug; 99(8):e762-e774. PubMed ID: 35667837
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
Hoch M; D'Ambrosio D; Wilbraham D; Brossard P; Dingemanse J
Eur J Pharm Sci; 2014 Oct; 63():147-53. PubMed ID: 25046167
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN;
Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976
[TBL] [Abstract][Full Text] [Related]
13. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.
Brossard P; Scherz M; Halabi A; Maatouk H; Krause A; Dingemanse J
J Clin Pharmacol; 2014 Feb; 54(2):179-88. PubMed ID: 24408162
[TBL] [Abstract][Full Text] [Related]
14. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
17. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
